Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 27, 2025Open Access

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AZAlex ZadroAAAlberto J. ArribasMRMichela Robusto

Discussion

Loading...

Member takes

Overview

High-throughput screening identifies resistance mechanisms in marginal zone lymphoma, suggesting PLK1 inhibition enhances anti-proliferative activity with BTK inhibitors.

Key Points

  • Combination treatment with PLK1 inhibitor rigosertib and BTK inhibitor zanubrutinib shows potential in overcoming BTK resistance.
  • The combination treatment reduced phosphorylation of BCR pathway components and altered transcriptomic profiles in lymphoma cells.
  • High-throughput screening of 1,695 compounds revealed rigosertib as a promising candidate to improve clinical efficacy in MZL.
  • Significant changes were observed in pathways related to B-cell activation and signaling, indicating a novel therapeutic strategy.

Cite This Study

Zadro et al. (2025) studied this question.

synapsesocial.com/papers/68ff87e2c8c50a61f2bdd12chttps://doi.org/10.1101/2025.10.25.684506
View Full Paper
Ask AI
Bookmark
Share